For NCE being developed for Major Depressive Disorder (MDD)
Suven Life Sciences announced that its drug discovery portfolio which has expanded into several new therapeutic areas such as Major Depressive Disorder (MDD), Obesity and Pain through Neuronal Nicotinic Receptor modulators resulted in the grant of one (1) product patent from Australia (2010337837), two product patents from Japan (5536227, 5588018) and one (1) product patent from Hong Kong (1174913) corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030.The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).
With these new patents, Suven has a total of nineteen (19) granted patents from Australia, fourteen (14) granted patents from Japan and fifteen (15) granted patents from Hong Kong.
Powered by Capital Market - Live News
